298eP Preliminary results of a multicenter, open-label, randomized, phase II trial (ALTER-PA-001 trial) of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer

Nab-paclitaxel and gemcitabine (AG) are standard first-line therapy in metastatic pancreatic cancer (mPC) with limited efficacy. Anlotinib is an oral multi-targeted TKI, mainly block VEGFR pathways. Benmelstobart is a humanized PD-L1 monoclonal antibody. Anlotinib plus benmelstobart has been approved as standard therapy in several solid tumors. This randomized phase II trial aims to evaluate the efficacy and safety of anlotinib plus benmelstobart and AG versus AG as first-line treatment for mPC patients.

Authors

Institutions

Publication Details

Journal
Immuno-Oncology Technology
Published
2025-12-01
DOI
https://doi.org/10.1016/j.iotech.2025.101497
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

298eP Preliminary results of a multicenter, open-label, randomized, phase II trial (ALTER-PA-001 trial) of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer

J. Cao, W. Li, X. Qu, Z. Li et al.
Immuno-Oncology Technology
Lung Cancer Research Studies
article

298eP Preliminary results of a multicenter, open-label, randomized, phase II trial (ALTER-PA-001 trial) of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer

J. Cao, W. Li, X. Qu, Z. Li, D M Li, Y. Lu, J. Wu, M. Quan, G. Yao, M. Zhang, L. Wang, J. Cui
article en

Abstract

Nab-paclitaxel and gemcitabine (AG) are standard first-line therapy in metastatic pancreatic cancer (mPC) with limited efficacy. Anlotinib is an oral multi-targeted TKI, mainly block VEGFR pathways. Benmelstobart is a humanized PD-L1 monoclonal antibody. Anlotinib plus benmelstobart has been approved as standard therapy in several solid tumors. This randomized phase II trial aims to evaluate the efficacy and safety of anlotinib plus benmelstobart and AG versus AG as first-line treatment for mPC patients.

Immuno-Oncology TechnologyVol. 28
Qingdao University (CN), Harbin Medical University (CN), Anhui Medical University (CN), Renji Hospital (CN), Sir Run Run Shaw Hospital (CN), Soochow University (CN), Third Affiliated Hospital of Harbin Medical University (CN), Affiliated Hospital of Qingdao University (CN), Shanghai East Hospital (CN), The First People’s Hospital of Lianyungang (CN), First Affiliated Hospital of Henan University of Science and Technology (CN), First Affiliated Hospital of Anhui Medical University (CN), First Hospital of China Medical University (CN), First Affiliated Hospital of Soochow University (CN), Hangzhou Cancer Hospital (CN), China Medical University (CN)
Good health and well-being
Openalex Percentile: Top 30%
Lung Cancer Research Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

298eP Preliminary results of a multicenter, open-label, randomized, phase II trial (ALTER-PA-001 trial) of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer — J. Cao, W. Li, et al. · Immuno-Oncology Technology (2025) | TGRS Research Map | TGRS